# A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.

> **NCT06746545** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib+S-1

## Key facts

- **NCT ID:** NCT06746545
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06746545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06746545, "A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06746545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*